ATE241982T1 - Verfahren zur hemmung von diabetischen komplikationen - Google Patents

Verfahren zur hemmung von diabetischen komplikationen

Info

Publication number
ATE241982T1
ATE241982T1 AT99955093T AT99955093T ATE241982T1 AT E241982 T1 ATE241982 T1 AT E241982T1 AT 99955093 T AT99955093 T AT 99955093T AT 99955093 T AT99955093 T AT 99955093T AT E241982 T1 ATE241982 T1 AT E241982T1
Authority
AT
Austria
Prior art keywords
diabetic complications
instant invention
post
age formation
methods
Prior art date
Application number
AT99955093T
Other languages
English (en)
Inventor
John W Baynes
Suzanne R Thorpe
Thorsten P Degenhardt
Raja Gabriel Khalifah
Billy Hudson
Nathan Alderson
Original Assignee
Univ South Carolina
Kansas University Medical Ct R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina, Kansas University Medical Ct R filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE241982T1 publication Critical patent/ATE241982T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AT99955093T 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen ATE241982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10518298P 1998-10-22 1998-10-22
PCT/US1999/024611 WO2000023063A2 (en) 1998-10-22 1999-10-21 Methods for inhibiting diabetic complications

Publications (1)

Publication Number Publication Date
ATE241982T1 true ATE241982T1 (de) 2003-06-15

Family

ID=22304498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955093T ATE241982T1 (de) 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen

Country Status (8)

Country Link
EP (1) EP1121121B1 (de)
JP (1) JP3864050B2 (de)
AT (1) ATE241982T1 (de)
AU (2) AU762030B2 (de)
CA (1) CA2347117C (de)
DE (1) DE69908630T2 (de)
ES (1) ES2197689T3 (de)
WO (1) WO2000023063A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036109A2 (en) * 2000-11-02 2002-05-10 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
ES2374399T3 (es) * 2003-06-20 2012-02-16 Nephrogenex, Inc. Piridoxamina para uso en el tratamiento de nefropatía diabética en diabetes tipo ii.
EP2269601A1 (de) 2003-10-27 2011-01-05 City of Hope LR-9, LR-74 and LR-90 zur Verwendung in der Behandlung von Diabetes-bedingten Komplikationen
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
CA2624090A1 (en) * 2005-05-24 2006-11-30 Tokai University Educational System Peritoneum protecting agent
WO2008013660A2 (en) * 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
CA2806256A1 (en) * 2010-07-23 2012-01-26 Tokai University Educational System Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same
JP6148127B2 (ja) * 2013-09-09 2017-06-14 株式会社パーマケム・アジア ピリドキサール・アミノグアニジン誘導体またはそれらの塩、及び、その製造方法
JP6585060B2 (ja) 2014-08-29 2019-10-02 株式会社レナサイエンス ピリドキサミン化合物及びチアミン化合物を組み合わせてなる医薬組成物
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
AU2017324935B2 (en) * 2016-09-06 2021-10-21 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
CN114502546A (zh) 2019-08-01 2022-05-13 普拉特戈公司 晚期糖基化终产物的抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH607773A5 (en) * 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
FR2349330A1 (fr) * 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
KR920700632A (ko) * 1990-02-19 1992-08-10 요시다 쇼오지 메일라드 반응저해제
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
JPH10158244A (ja) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd ５−アミノアルキル−４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
JPH10175954A (ja) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd ４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤

Also Published As

Publication number Publication date
CA2347117C (en) 2006-01-24
JP2002527471A (ja) 2002-08-27
AU762030B2 (en) 2003-06-19
DE69908630T2 (de) 2004-04-29
WO2000023063A3 (en) 2000-07-13
DE69908630D1 (de) 2003-07-10
EP1121121A2 (de) 2001-08-08
AU2003248205A1 (en) 2003-10-30
AU1127400A (en) 2000-05-08
WO2000023063A2 (en) 2000-04-27
JP3864050B2 (ja) 2006-12-27
CA2347117A1 (en) 2000-04-27
ES2197689T3 (es) 2004-01-01
EP1121121B1 (de) 2003-06-04

Similar Documents

Publication Publication Date Title
DE69908630D1 (de) Verfahren zur hemmung von diabetischen komplikationen
EA200100702A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
ATE409037T1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
LV12687B (lv) Aterosklerozes arstesanas panemiens izmantojot ap2 inhibitoru un to saturosas kombinacijas
DE69726815D1 (de) Verfahren zur Frakturierung von unterirdischen Lagerstätten
DE60101669D1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE540681T1 (de) Verfahren zur behandlung von atherosklerose
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
DE69806970D1 (de) Verfahren zur behandlung von hartgeweben
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
DE69218202D1 (de) Verfahren zur behandlung von fluoroaluminosilikatgläsern
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
DE69904156D1 (de) Verfahren zur inhibierung der ablagerung von weisspech in der papierherstellung
EP1200538A4 (de) Verfahren zur behandlung von petroleumsäuren
WO2000021516A3 (en) Methods for inhibiting diabetic complications
EP1435979A4 (de) Verfahren zur behandlung von multipler sklerose
DE60016755D1 (de) Verfahren zur behandlung von rohöl
DE69817080D1 (de) Verfahren zur Verminderung des Sauregehalts von Rohöl
DE69409297D1 (de) Verfahren zur Vernetzung von Organosiloxanzusammensetzungen bei Anwesenheit von Vernetzungsinhibitoren
DE60119671D1 (de) Verfahren zur Behandlung von Holzwerkstoff
EP1009421A4 (de) Verfahren und zusammenstellungen zur verbesserten wundheilung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties